COMMUNIQUÉS West-GlobeNewswire

Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
28/03/2024
Collaborative Study involving the VA and UCSD achieved statistically significant decrease in PCS and PTSD symptoms versus control group The data supports the Company’s strategy to offer military and civilian physicians [...]
SweetWater Brewing Launches Hammer Red Amber Ale to Support Georgia Aquarium
28/03/2024
The Limited-Release Seasonal Is Part of SweetWater’s On-going Partnership with Georgia Aquarium ATLANTA, March 28, 2024 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest [...]
Psychemedics Corporation Reports 2023 Financial Results
28/03/2024
DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023 [...]
Biomerica InFoods IBS Data to be Presented at the Upcoming Digestive Disease Week (DDW) 2024 Conference
28/03/2024
Collaborators at the University of Michigan will present new Data on InFoods ® IBS in the DDW Irritable Bowel Syndrome (IBS) Clinical Session IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: [...]
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis
28/03/2024
As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN ® Nasal Spray and build on its longstanding efforts with [...]
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
28/03/2024
HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
28/03/2024
AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of [...]
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
28/03/2024
On track for topline data from CAN-2409 phase 3 in localized intermediate/high risk prostate cancer, expected in Q4 2024 Results from ongoing, first-in-human, phase 1b clinical trial of CAN-3110, in recurrent high-grade [...]
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
28/03/2024
Live webcast presentation on Wednesday, April 3rd at 1:35 PM ET OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS [...]
Unity Consortium Marks Adolescent Immunization Action Week (AIAW) with activities to help Parents and Adolescents get up to date on Recommended Vaccines
28/03/2024
Unity encourages parents and adolescents to Stay on TASK during AIAW, April 1-5 VENTNOR CITY, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- UNITY® Consortium, a non-profit organization focused on preventive health and [...]
Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
28/03/2024
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 [...]
Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
28/03/2024
WARREN, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings ('Tevogen Bio') ( Nasdaq : TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell [...]
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
28/03/2024
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and [...]
Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL
28/03/2024
Providence, RI, March 28, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. ( NASDAQ: OCEA ), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, today [...]
Lowell Farms Inc. Announces Audited Fourth Quarter and Fiscal Year 2023 Financial and Operational Results
28/03/2024
SALINAS, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California cannabis company with advanced distribution and production capabilities including extraction [...]
Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors
28/03/2024
David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair LONDON, March 28, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company [...]
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
28/03/2024
- New 12-month data from the Phase 3 BOND-003 trial to be featured in an oral presentation in the Paradigm-shifting, Practice-changing Clinical Trials in Urology plenary session - IRVINE, Calif., March 28, 2024 (GLOBE [...]
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
28/03/2024
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum PB2 inhibitor [...]
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
28/03/2024
Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic fibrosis (CF) [...]

Pages